TerminatedPhase NA

Incretin and KATP Channels

Effects of KATP Channel Blockers on GLP-1 and Its Analogues' Mediated Microvascular Function

Lead sponsor

Katarina Kos

Assets

Exenatide / Liraglutide

Listed sites

Recruiting sites

Actual enrollment

Study population

Healthy volunteers

Eligibility highlights

•BMI ≤25

Primary endpoint

•Skin blood flow to GLP-1 and its analogues

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT01934816

Org study ID2Myo2013

Secondary ID13/SW/0010REC

Secondary ID1308823Trust Research and Development

Timeline

Milestones

Study first posted2013-09-04estimated

Last update posted2017-02-17actual

Study start2013-06actual (month precision)

Primary completion2015-01actual (month precision)

Study completion2015-10actual (month precision)

Assets

Investigational agents

Exenatide Liraglutide

Who this study enrolls

Healthy volunteers

Who can enroll

Minimum age18 Years

Maximum age70 Years

SexAll

Healthy volunteersAccepted

Inclusion criteria

•BMI ≤ 25 kg/m2

Exclusion criteria

•current or past history of diabetes (HbA1C more or equal 45mmol/mol)

•history of postprandial hypoglycaemia and dumping syndrome

•established cardiovascular disease

•established cerebrovascular disease

•blood pressure ≥ 140/85 mmHg

•Raynaud's disease

•severe impairment of renalhepatic, thyroid or adrenocortical function

•current treatment with any anti-hypertensive treatment

•lipid lowering therapy or systemic steroids

•lactation, pregnancy

•established vascular disease

•bariatric surgery

•significant weight change within the last 3 months

Endpoints (1)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Other (unclassified)

1 endpoint

Primary/protocol endpoint/low confidence

Change in skin blood flow to GLP-1 and its analogues

Time frame:6 weeks

change from baseline, descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 6, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.